Who is sponsoring NCT03975374?

NCT03975374 is sponsored by Sutphin Drugs.

What drugs are being tested in NCT03975374?

Interventions in NCT03975374: Tobramycin/dexamethasone opthalmic solution, Tobradex Opthalmic Solution.

What condition does NCT03975374 study?

NCT03975374 studies Blepharo Conjunctivitis.

Is NCT03975374 still recruiting?

NCT03975374 is currently status unknown. Last updated 5 June 2019.

Last reviewed 2019-06-05 · How we verify

NCT03975374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

Status unknown EARLY_PHASE1 Last updated 5 June 2019

What this trial tests

EARLY_PHASE1 trial testing Tobramycin/dexamethasone opthalmic solution in Blepharo Conjunctivitis in 5,000 participants. Status unknown.

Timeline

15 June 2019

Primary endpoint
1 July 2019

30 June 2020

Quick facts

Lead sponsor	Sutphin Drugs
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	5,000
Start date	15 June 2019
Primary completion	1 July 2019
Estimated completion	30 June 2020
Sites	1 location across United States

Drugs / interventions tested

Tobramycin/dexamethasone opthalmic solution — full drug profile →
Tobradex Opthalmic Solution — full drug profile →

Conditions studied

Blepharo Conjunctivitis — all drugs for Blepharo Conjunctivitis →

Sponsor

Sutphin Drugs — full company profile →

Who can join

18 and older, any sex, with Blepharo Conjunctivitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sutphin Drugs trials

Trials by the same sponsor.

NCT04502277 — Bioavailability of Flucanazole · EARLY_PHASE1 · unknown
NCT04113772 — Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine · NA · unknown
NCT03975205 — To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames · EARLY_PHASE1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03975374 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sutphin Drugs
Last refreshed: 5 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing